Showing results (51-60 of 157) with videos related to
Sort By:
Pageof 16
The American Journal of Cardiology|June 1, 1990
Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experienceR P Byington, J Worthy, T Craven, et al.Journal of Internal Medicine|May 1, 1994
Overtreatment and undertreatment of hypertensionC D Furberg, G Berglund, T A Manolio, et al.American Journal of Hypertension|June 20, 1998
Cost-minimization and the number needed to treat in uncomplicated hypertensionK A Pearce, C D Furberg, B M Psaty, et al.Archives of Internal Medicine|February 11, 2000
Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) InvestigatorsM Miller, R Byington, D Hunninghake, et al.BMJ (Clinical Research Ed.)|April 7, 1990
Long term propranolol treatment and changes in body weight after myocardial infarctionS Rössner, C L Taylor, R P Byington, et al.Annals of Internal Medicine|December 19, 2001
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of HypertensionC D Furberg, B M Psaty, M Pahor, et al.Journal of Clinical Pharmacy and Therapeutics|August 9, 2001
Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapyH Sinzinger, G Lupattelli, F Chehne, et al.Annals of Medical and Health Sciences Research|September 4, 2014
Evaluation of self medication practices in rural area of town sahaswan at northern IndiaA Ahmad, I Patel, Gp Mohanta, et al.Journal of Human Hypertension|December 5, 2008
Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertensionR Balkrishnan, H Phatak, G Gleim, et al.Journal of Drugs in Dermatology : JDD|August 12, 2004
Improved quality of life with effective treatment of facial melasma: the pigment trialR Balkrishnan, A P Kelly, A McMichael, et al.Pageof 16